Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

American Journal of Cardiology

Volumn 80, Issue 3, 1997, Pages 287-293

  Downs, John R ^a   Beere, Polly A ^a   Whitney, Edwin ^a   Clearfield, Michael ^a   Weis, Stephen ^a   Rochen, Jeffrey ^a   Stein, Evan A ^a   Shapiro, Deborah R ^a   Langendorfer, Alexandra ^a   Gotto Jr , Antonio M ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; FAT INTAKE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES; UNSTABLE ANGINA PECTORIS;

AGED; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DIET, FAT-RESTRICTED; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; MILITARY MEDICINE; RESEARCH DESIGN; TEXAS; TREATMENT OUTCOME; UNITED STATES;

EID: 2042503551     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00347-0     Document Type: Article

References (27)

1. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms [review]. N Engl J Med. 332:1995;512-521.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality 30 years of follow-up from the Framingham study. JAMA. 257:1987;2176-2180.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828.
4. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee D-J, Sherwin R, Shih J, Stamler J, Wentworth D. Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 152:1992;1490-1500.
5. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:1995;69C-77C.
6. 21 precipitation procedures for quantification of high density lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 18:1977;499-502.
8. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry Standardization Project for measurements of Apolipoproteins A-I and B-II: evaluation and selection of candidate reference materials. Clin Chem. 38:1992;658-662.
9. Myers GL, Cooper GR, Winn CL, Smoth SJ. The Centers for Disease Control-National Heart Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 9:1989;105-135.
10. SAS Institute Inc. (1991) SAS® Technical Report P-217 SAS/STAT® Software: The PHREG Procedure Version 6.
11. Hwang IK, de Cani JS, Shih WJ. Group sequential tests using a family of type I error spending rate functions. Stat Med. 9:1990;1439-1445.
12. Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics. 36:1980;343-346.
13. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
14. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaltaniemi P, Koskinen P, Manninen V, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 317:1987;1237-1245.
15. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. revention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
16. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
17. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79:1989;8-15.
18. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA. 256:1986;2835-2838.
19. Manninen V, Tenkanen L, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 85:1992;37-45.
20. Whitney EJ, Shear CL, Mantell G, Lydick E, Wolf R. The case for unstable angina pectoris as a primary end point in primary prevention studies. Am J Cardiol. 70:1992;738-741.
21. Wellford AL, Ashcom TL, Whitney EJ, Rubal BJ, Wellford LA, Moody JM. Changing presentation of coronary heart disease in an inpatient population within the U.S. military health care system. Mil Med. 158:1993;598-603.
22. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
23. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 346:1995;1467-1471.
24. Rose G, Shipley M. Effects of coronary risk reduction on causes of death. Lewis B, Assmann G. The Social and Economic Contexts of Coronary Prevention. 1990;24-31 Current Medical Literature Ltd, London.
25. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JI. The cholesterol facts. Circulation. 81:1990;1721-1733.
26. Henry RR, Genuth S. Forum one: current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 124:((1pt 2)):1996;175-177.
27. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 75:1995;1130-1133.